WO1999052912A1 - PROCEDE DE PREPARATION D'UN COMPOSE β-LACTAME HALOGENE - Google Patents
PROCEDE DE PREPARATION D'UN COMPOSE β-LACTAME HALOGENE Download PDFInfo
- Publication number
- WO1999052912A1 WO1999052912A1 PCT/JP1999/001736 JP9901736W WO9952912A1 WO 1999052912 A1 WO1999052912 A1 WO 1999052912A1 JP 9901736 W JP9901736 W JP 9901736W WO 9952912 A1 WO9952912 A1 WO 9952912A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acid
- nucleophilic
- lactam
- halogenated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/10—Modification of an amino radical directly attached in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
Definitions
- the present invention relates to a method for producing a halogenated 3-lactam compound containing a haguchigenated penum derivative or a haguchigenidani cefm derivative, which is a synthetic intermediate of a pharmaceutical.
- a halogenated 3-lactamid conjugate obtained in the present invention include, for example, 6,6-dibromodinisilaneic acid, which is an intermediate of sulbactam which is one of antibacterial agents (Japanese Patent Application Laid-Open No. 557-1721). No. 15). Background art
- the former method requires the use of a halogen-based organic solvent such as methylene chloride or carbon tetrachloride.
- halogenated organic solvents are severely restricted for use on a large scale due to safety and environmental pollution problems, and carbon tetrachloride is a solvent that cannot be used or even obtained. Therefore, a method for producing a halogenated ⁇ -lactam conjugate in a system without using an organic solvent has been desired in the section.
- the latter method which does not use an organic solvent, has a remarkably low yield of 34%, and is not very practical.
- An object of the present invention is to use an organic solvent, which has many problems from the viewpoint of safety and environmental pollution.
- an i3-latatam-type amino compound represented by the general formula (1) is reacted with nitrous acid or nitrite in water under acidic conditions in a slurry monodispersed state in water in the presence of a halogen molecule.
- the present invention relates to a method for producing a halogenated
- N represents an integer of 0 to 2.
- A represents the formula (2) or (3).
- R ⁇ R 2 are the same or different and each represents a hydrogen atom, a halogen atom, an alkyl group of Ci Cg, C 2 ⁇ C 4 of ⁇ alkenyl group, an alkynyl group of C 2 -C 4, nucleophilic group, or CH 2 R 3 And R 3 represents a halogen atom or a nucleophilic group.
- X 1 represents a hydrogen atom or a halogen atom.
- X 2 represents a halogen atom.
- the use of an organic solvent which has many problems from the viewpoint of safety and environmental pollution, is avoided, and a simple and inexpensive production method using water as a main solvent is established.
- a 3-lactam-based amino compound represented by the general formula (1) was reacted in water in a slurry-dispersed state to form a halogenated lactam represented by the general formula (4).
- the inventors have found that the compounds can be produced on a large scale and efficiently and completed the present invention.
- the halogen atom in the substituents RR 2 and R 3 of the present invention is chlorine, bromine and iodine.
- Examples of the C 1 C g alkynole group include methyl, ethyl, and propyl; C 2 -C 4 alkenyl groups include vinyl, propenyl, arinole, and butenyl; and C 2 -C 4 alkynyl groups. Etul, propargyl, butynyl and the like.
- nucleophilic group in the substituents R 1 R 2 and R 3 of the present invention examples include an acetyloxy group, a propionyloxy group, a 3-oxobutyryloxy group, a 3-carboxypropionyloxy group, and a 4-carboxy group.
- Aliphatic acyloxy groups having 2 to 4 carbon atoms such as a butyryloxy group, aromatic acyloxy groups such as a mandelyloxy group and a 2-carboxybenzoyloxy group, carbamoyloxy group, a hydroxy group, a mercapto group, or a derivative thereof.
- the nucleus group may be further substituted with an alkyl group having 1 to 3 carbon atoms, an aliphatic acyl group having 1 to 3 carbon atoms, and the number of substituents is usually preferably 1 to 2.
- the nucleophilic group in the substituents RR 2 and R 3 of the present invention also includes, for example, a heterocyclic group bonded via S, that is, a heterocyclic thio group.
- the hetero ring is a 5- to 6-membered ring containing 1 to 4 heteroatoms selected from 0, S or N.
- hetero rings examples include a pyridyl group, a pyridazinyl group, a pyrazolyl group, a thiazolinole group, a thiadiazolyl group, a triazolinole group, and a tetrazolinole group. Further, these hetero rings may have a substituent such as a lower alkyl group having 1 to 3 carbon atoms.
- the halogen atom represented by X 1 and X 2 in the halogenated 3-lactam compound represented by the general formula (4) is chlorine, bromine and iodine.
- acidic conditions are obtained by adding an acid.
- the acid used examples include sulfuric acid, hydrohalic acid, and nitric acid.
- the amount of the acid to be used for the compound represented by the general formula (1) is usually 1 to 20 equivalents, but preferably 1.5 to 6 equivalents.
- Halogen molecules used in the present invention include bromine, iodine and chlorine.
- the amount of the halogen molecule to be used for the compound represented by the general formula (1) is usually 1 to 16 equivalents, but preferably 2 to 6 equivalents.
- the nitrite used in the present invention is preferably sodium nitrite, nitrous acid lime or the like.
- the amount of nitrous acid or nitrite used for the compound represented by the general formula (1) is usually 1 to 12 equivalents, but preferably 2 to 6 equivalents.
- the reaction of the present invention is usually carried out at normal pressure, but may be carried out under pressure if necessary.
- the reaction temperature is preferably about 10 to 15 ° C., more preferably 5 to 6. It is.
- reaction time varies depending on the reaction temperature, the substrate concentration and the number of reagent equivalents, but is usually preferably about 6 to 36 hours, particularly preferably 12 to 24 hours.
- the desired high-purity] 3-lactam compound can be efficiently obtained only by conducting the reaction in a closed vessel or a non-closed vessel, and filtering the precipitated crystals after the reaction. Purification can also be performed using a purification method such as ordinary recrystallization. BEST MODE FOR CARRYING OUT THE INVENTION
- This slurry is added to the above mixture in small portions over a period of 12 hours while maintaining the temperature below 6 ° C. After stirring the above mixture at 6 ° C or less for 1 hour, the gas phase is replaced with air. Add aqueous sodium bisulfite until the reaction mixture in the slurry changes from brown to pale yellow. After filtering off the product, the product is washed with 240 ml of water to obtain about 58 g of 7,7-dibromodecetinolecephalosporanic acid. (Yield 87%)
- potassium permanganate prepared with 59.3 g of potassium permanganate, 18 ml of concentrated phosphoric acid and 600 ml of water
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/424,259 US6274730B1 (en) | 1998-04-09 | 1999-02-04 | Process for producing halogenated β-lactam compound |
KR10-1999-7011263A KR100373592B1 (ko) | 1998-04-09 | 1999-04-02 | 할로겐화 β-락탐화합물의 제조법 |
CA002292557A CA2292557C (en) | 1998-04-09 | 1999-04-02 | Process for preparing halogenated .beta.-lactam compounds |
EP99910811A EP0989132B1 (en) | 1998-04-09 | 1999-04-02 | Process for producing halogenated beta-lactam compound |
DE69936428T DE69936428T2 (de) | 1998-04-09 | 1999-04-02 | Verfahren zur herstellung halogenierter beta-lactamverbindungen |
HK00108441A HK1029115A1 (en) | 1998-04-09 | 2000-12-28 | Process for producing halogenated b-lactam compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/116187 | 1998-04-09 | ||
JP11618798A JP3236261B2 (ja) | 1998-04-09 | 1998-04-09 | ハロゲン化β−ラクタム化合物の製造法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999052912A1 true WO1999052912A1 (fr) | 1999-10-21 |
Family
ID=14680986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/001736 WO1999052912A1 (fr) | 1998-04-09 | 1999-04-02 | PROCEDE DE PREPARATION D'UN COMPOSE β-LACTAME HALOGENE |
Country Status (12)
Country | Link |
---|---|
US (1) | US6274730B1 (ja) |
EP (1) | EP0989132B1 (ja) |
JP (1) | JP3236261B2 (ja) |
KR (1) | KR100373592B1 (ja) |
CN (1) | CN1125825C (ja) |
AT (1) | ATE366255T1 (ja) |
CA (1) | CA2292557C (ja) |
DE (1) | DE69936428T2 (ja) |
ES (1) | ES2288773T3 (ja) |
HK (1) | HK1029115A1 (ja) |
TW (1) | TWI236468B (ja) |
WO (1) | WO1999052912A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104262359A (zh) * | 2014-09-29 | 2015-01-07 | 江西富祥药业股份有限公司 | 一种舒巴坦酸的合成方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100399951B1 (ko) | 1998-12-30 | 2003-12-18 | 주식회사 하이닉스반도체 | 칼라이미지센서제조방법 |
CN102952147B (zh) * | 2011-08-16 | 2015-04-08 | 台州市信友医药化工有限公司 | 一种舒巴坦酸的合成方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4276285A (en) * | 1977-06-07 | 1981-06-30 | Pfizer Inc. | Combinations of penicillanic acid 1,1-dioxide with 7-(D-2-[4-ethylpiperazin-2,3-dione-1-carboxamido]-2-[4-hydroxyphenyl]acetamido)-3-([1-methyl-5-tetrazolyl]thiomethyl)-3-desacetoxymethylcephalosporanic acid |
-
1998
- 1998-04-09 JP JP11618798A patent/JP3236261B2/ja not_active Expired - Lifetime
-
1999
- 1999-02-04 US US09/424,259 patent/US6274730B1/en not_active Expired - Lifetime
- 1999-04-02 AT AT99910811T patent/ATE366255T1/de active
- 1999-04-02 ES ES99910811T patent/ES2288773T3/es not_active Expired - Lifetime
- 1999-04-02 KR KR10-1999-7011263A patent/KR100373592B1/ko not_active IP Right Cessation
- 1999-04-02 EP EP99910811A patent/EP0989132B1/en not_active Expired - Lifetime
- 1999-04-02 CN CN99800517A patent/CN1125825C/zh not_active Expired - Lifetime
- 1999-04-02 WO PCT/JP1999/001736 patent/WO1999052912A1/ja active IP Right Grant
- 1999-04-02 CA CA002292557A patent/CA2292557C/en not_active Expired - Fee Related
- 1999-04-02 DE DE69936428T patent/DE69936428T2/de not_active Expired - Lifetime
- 1999-04-02 TW TW088105263A patent/TWI236468B/zh not_active IP Right Cessation
-
2000
- 2000-12-28 HK HK00108441A patent/HK1029115A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4276285A (en) * | 1977-06-07 | 1981-06-30 | Pfizer Inc. | Combinations of penicillanic acid 1,1-dioxide with 7-(D-2-[4-ethylpiperazin-2,3-dione-1-carboxamido]-2-[4-hydroxyphenyl]acetamido)-3-([1-methyl-5-tetrazolyl]thiomethyl)-3-desacetoxymethylcephalosporanic acid |
Non-Patent Citations (1)
Title |
---|
VOLKMANN R. A., ET AL.: "EFFICIENT PREPARATION OF 6,6-DIHALOPENICILLANIC ACIDS. SYNTHESIS OF PENICILLANIC ACID S,S-DIOXIDE (SULBACTAM).", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 47., 1 January 1982 (1982-01-01), US, pages 3344/3345., XP000197450, ISSN: 0022-3263, DOI: 10.1021/jo00138a035 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104262359A (zh) * | 2014-09-29 | 2015-01-07 | 江西富祥药业股份有限公司 | 一种舒巴坦酸的合成方法 |
CN104262359B (zh) * | 2014-09-29 | 2017-02-15 | 江西富祥药业股份有限公司 | 一种舒巴坦酸的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0989132A1 (en) | 2000-03-29 |
HK1029115A1 (en) | 2001-03-23 |
JPH11292882A (ja) | 1999-10-26 |
KR100373592B1 (ko) | 2003-02-26 |
CA2292557A1 (en) | 1999-10-21 |
CN1125825C (zh) | 2003-10-29 |
TWI236468B (en) | 2005-07-21 |
US6274730B1 (en) | 2001-08-14 |
EP0989132B1 (en) | 2007-07-04 |
EP0989132A4 (en) | 2001-11-14 |
ATE366255T1 (de) | 2007-07-15 |
ES2288773T3 (es) | 2008-01-16 |
CA2292557C (en) | 2007-05-22 |
KR20010013271A (ko) | 2001-02-26 |
CN1263530A (zh) | 2000-08-16 |
JP3236261B2 (ja) | 2001-12-10 |
DE69936428D1 (de) | 2007-08-16 |
DE69936428T2 (de) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3421354B2 (ja) | 結晶性セフジニルアミン塩 | |
US6458949B1 (en) | Ceftiofur, its intermediate and a process for the preparation of the same | |
WO1999052912A1 (fr) | PROCEDE DE PREPARATION D'UN COMPOSE β-LACTAME HALOGENE | |
JPH0246587B2 (ja) | ||
KR20020068518A (ko) | 페니실린 결정 및 그 제조 방법 | |
KR101266330B1 (ko) | 베타-락탐 생성물의 정제 | |
US20050043531A1 (en) | Process for preparing cefepime | |
RO109652B1 (ro) | Procedeu pentru prepararea unui antibiotic cefepim dihidroclorura hidrat | |
JPH025758B2 (ja) | ||
WO1999020631A1 (fr) | Procede de production de composes de 3 cephems | |
JP2595605B2 (ja) | 2−置換オキシイミノ−3−オキソ酪酸の製造法 | |
US4237280A (en) | Intermediate for cephalosporin type compound | |
JPH03181485A (ja) | 7―(d―2―アミノ―2―フェニルアセトアミド)―3―セフェム―4―カルボン酸一水和物の製造方法及びその方法で生成される中間体 | |
JP4610737B2 (ja) | 置換されたピリジンカルボン酸の改善された製造方法 | |
JPS62212391A (ja) | セフエムアルコキシ基の脱離法 | |
KR930007816B1 (ko) | 세펨 화합물의 새로운 제조방법 | |
KR100432425B1 (ko) | 세펨 유도체 또는 그 염의 신규한 제조방법 | |
JP2898029B2 (ja) | セフェム誘導体ジメチルホルムアミド溶媒和結晶 | |
JPWO2019240140A1 (ja) | 固体状トリアゾリンジオン化合物の製造方法および固体状トリアゾリンジオン化合物、ならびにトリアゾリンジオン化合物の製造方法 | |
JPS6242988A (ja) | セフエム化合物のメトキシ化法 | |
López et al. | Improvement of the synthesis of diphenylmethyl 7β-(o-hydroxy) benzylideneamino-3-hydroxymethyl-3-cephem-4-carboxylate | |
JPWO2005092869A1 (ja) | 1,2−ベンズイソキサゾール−3−メタンスルホンアミドのワンポット製造法 | |
JPS5924158B2 (ja) | 抗菌剤の製法 | |
JPS61109771A (ja) | ピラゾ−ル誘導体およびその製法 | |
JPH0517229B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99800517.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2292557 Country of ref document: CA Ref document number: 2292557 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09424259 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997011263 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999910811 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1999910811 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997011263 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997011263 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999910811 Country of ref document: EP |